Europe
Drug development requires solid funding. Here’s who’s standing on higher ground this week with fresh investment dollars.
The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
The Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks the life cycle of the mosquito-borne parasite that causes malaria.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
It was another busy week for clinical trial announcement. Here’s a look.
The tiny heart organoids, dubbed “cardioids,” even begun beating similarly as real miniature hearts, making them the most realistic heart organoids developed to date.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
PRESS RELEASES